Amedisys (AMED) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Mizuho Securities Upgrades Amedisys (AMED) to Buy; Pay Up for Strong Management
May 3, 2017 7:30 AM EDTMizuho Securities upgraded Amedisys (NASDAQ: AMED) from Neutral to Buy with a price target of $65.00.
Analyst Sheryl Skolnick is positive on management amid Q1 results. "AMED's 1Q17 result demonstrates just that: not only are cost savings real, but the balanced approach to... More
